223 related articles for article (PubMed ID: 19738118)
1. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki AB; Koziner B; Chanan-Khan AA; Seymour JF; Gribben J; Itri LM; Rai KR
J Clin Oncol; 2009 Nov; 27(31):5208-12. PubMed ID: 19738118
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
Robak T; Warzocha K; Govind Babu K; Kulyaba Y; Kuliczkowski K; Abdulkadyrov K; Loscertales J; Kryachok I; Kłoczko J; Rekhtman G; Homenda W; Błoński JZ; McKeown A; Gorczyca MM; Carey JL; Chang CN; Lisby S; Gupta IV; Grosicki S
Leuk Lymphoma; 2017 May; 58(5):1084-1093. PubMed ID: 27731748
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
8. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
9. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
10. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
[TBL] [Abstract][Full Text] [Related]
11. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jäger U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Döhner H; Brittinger G; Emmerich B; Hallek M;
Blood; 2006 Feb; 107(3):885-91. PubMed ID: 16219797
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial.
Howard DR; Munir T; Hockaday A; Rawstron AC; Collett L; Oughton JB; Allsup D; Bloor A; Phillips D; Hillmen P
Trials; 2016 Sep; 17(1):456. PubMed ID: 27645620
[TBL] [Abstract][Full Text] [Related]
15. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
[TBL] [Abstract][Full Text] [Related]
18. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
[TBL] [Abstract][Full Text] [Related]
19. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
Kowal M; Dmoszyńska A; Lewandowski K; Hellmann A; Wegrzyn J; Skotnicki AB; Wołowiec D; Kuliczkowski K; Piszcz J; Kłoczko J; Roznowski K; Komarnicki M
Leuk Lymphoma; 2004 Jun; 45(6):1159-65. PubMed ID: 15359995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]